FAQ/Help |
Calendar |
Search |
Today's Posts |
08-31-2006, 05:35 PM | #1 | ||
|
|||
Junior Member
|
Just in case this hasn't been posted.
http://www.ncbi.nlm.nih.gov/entrez/q..._uids=15082580 : Gut. 2004 May;53(5):641-8. Links In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. • Korponay-Szabo IR, • Halttunen T, • Szalai Z, • Laurila K, • Kiraly R, • Kovacs JB, • Fesus L, • Maki M. Paediatric Research Centre, Tampere University Hospital, Tampere, Finland. BACKGROUND: IgA class serum autoantibodies against type 2 (tissue) transglutaminase (TG2) bind to both intestinal and extraintestinal normal tissue sections in vitro, eliciting endomysial, reticulin, and jejunal antibody reactions. It is not known whether similar binding also occurs in coeliac patients in vivo, and may thereby contribute to disease manifestations. AIMS: To investigate intestinal and extraintestinal coeliac tissues for the presence of in vivo bound TG2 specific IgA and its relation to small intestinal mucosal atrophy. PATIENTS: We investigated jejunal samples with normal villous morphology from 10 patients with developing coeliac disease who subsequently progressed to a flat lesion, from 11 patients with dermatitis herpetiformis, and from 12 non-coeliac controls. Six extrajejunal biopsy samples (liver, lymph node, muscle, appendix), obtained based on independent clinical indications from patients with active coeliac disease, were also studied. METHODS: Double colour immunofluorescent studies for in situ IgA, TG2, and laminin were performed. IgA was eluted from tissue sections and tested for TG2 specificity by enzyme linked immunosorbent assay and indirect immunofluorescence. RESULTS: IgA (in one IgA deficient case IgG) deposition on extracellularly located TG2 was detected in jejunal and extrajejunal specimens of all coeliac patients, and also in seven of 11 dermatitis herpetiformis patients, of whom two had no circulating endomysial antibodies. IgA eluted from extraintestinal coeliac tissues was targeted against TG2. CONCLUSIONS: Coeliac IgA targets jejunal TG2 early in disease development even when endomysial antibodies are not present in the circulation. Extraintestinal target sites of coeliac IgA further indicate that humoral immunity may have a pathogenetic role.PMID: 15082580 [PubMed - indexed for MEDLINE] |
||
Reply With Quote |
08-31-2006, 07:28 PM | #2 | ||
|
|||
Member
|
Ok, someone help me understand what is being said.
I think it says they found a tissue transglutaminase reaction in the gut tissue before the blood tests were positive. Would this have anything to do with the tissue transglutaminase Dr. Fine tests? Does he find the same thing by examining the stool? Guess we will have to read the complete article to find out where the extraintestinal sites mentioned are located. Anne |
||
Reply With Quote |
09-06-2006, 09:36 AM | #3 | ||||
|
|||||
Senior Member (jccglutenfree)
|
Here are others. I think they are all suggesting that these TG2-related immunoglobulin deposits can be found in patients who are sero-negative and despite normal small-bowel mucosal villous architecture.
Right???? Endomysial antibodies with normal histology indicates early developing coeliac disease. Transglutaminase 2-targeted intestinal autoantibody deposits proved the best predictor of subsequent coeliac disease. Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease. PMID: 16886921 Aug 2006 Quote:
Quote:
Quote:
Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. PMID: 16036509 May 2005 Quote:
__________________
. Last edited by jccgf; 09-06-2006 at 10:13 AM. |
||||
Reply With Quote |
Reply |
|
|